Resveratrol-containing gel for the treatment of acne vulgaris: A single-blind, vehicle-controlled, pilot study

American Journal of Clinical Dermatology

Volumn 12, Issue 2, 2011, Pages 133-141

  Fabbrocini, Gabriella ^a   Staibano, Stefania ^a   De Rosa, Giuseppe ^a   Battimiello, Valeria ^a   Fardella, Nunzio ^a   Ilardi, Gennaro ^a   Immacolata La Rotonda, Maria ^a   Longobardi, Amelia ^a   Mazzella, Marialuisa ^a   Siano, Maria ^a   Pastore, Francesco ^a   De Vita, Valerio ^a   Vecchione, Maria Luisa ^a   Ayala, Fabio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acne vulgaris, treatment; Research and development; Resveratrol, adverse reactions; Resveratrol, therapeutic use; Stilbenes, therapeutic use; Topical.

Indexed keywords

CARBOXYMETHYLCELLULOSE; CYANOACRYLATE; PHYTOALEXIN; RESVERATROL;

ACNE VULGARIS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMEDO; CYANOACRYLATE FOLLICULAR BIOPSY; DATA BASE; FEMALE; GRAPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROGEL; ISOMER; MALE; MEDICAL PHOTOGRAPHY; PILOT STUDY; PLANT; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SKIN BIOPSY; STORAGE TEMPERATURE;

ACNE VULGARIS; ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; CARBOXYMETHYLCELLULOSE SODIUM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; DRUG STORAGE; FEMALE; HUMANS; HYDROGELS; MALE; PHARMACEUTICAL VEHICLES; PHOTOGRAPHY; PILOT PROJECTS; PROPIONIBACTERIUM ACNES; SINGLE-BLIND METHOD; STILBENES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952136521     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11530630-000000000-00000     Document Type: Article

References (33)

1. GoodmanG.Acne and acne scarring: the case for active and early intervention. Aust Fam Physician 2006; 35: 503-4
2. Morohashi M, Toyoda M. Pathogenesis of acne: medical electron microscopy. Med Electron Microsc 2001; 34 (1): 29-40
3. Peck G, Olsen T, Yoder F, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979; 300: 329-33 (Pubitemid 9114884)
4. Strauss J, Rapini R, Shalita A, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984; 10: 490-6 (Pubitemid 14150139)
5. Newman MD, Bowe WP, Heughebaert C, et al. Therapeutic considerations for severe nodular acne. Am J Clin Dermatol 2011; 12: 7-14
6. Ganceviciene R, Zouboulis CC. Isotretinoin: state of the art treatment for acne vulgaris. J Dtsch Dermatol Ges 2010; 8: 47-59
7. Wysowski D, Pitts M, Beitz J. Depression and suicide in patients treated with isotretinoin [letter]. N Engl J Med 2001; 344: 460 (Pubitemid 32128686)
8. Jick S, Kremers H, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136: 1231-6
9. Zouboulis CC, Eady A, Philpott M, et al. What is the pathogenesis of acne? Exp Dermatol 2005; 14: 143-52
10. Norris JF, Cunliffe WJ. A histological and immunocytochemical study of early acne lesions. Br J Dermatol 1988; 118: 651-9
11. Jeremy AHT, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-7 (Pubitemid 36900450)
12. Auffret N. Pathophysiological advances in acne. Ann Dermatol Venereol 2010; 137 Suppl. 2: S52-6
13. Webster JF. Acne vulgaris. BMJ 2002 Aug 31; 325 (7362): 475-9
14. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-41 (Pubitemid 34809200)
15. Nagy I, Pivarcsi A, Koreck A, et al. Distinct strains of Propionibacterium acnes induce selective human b-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol 2005; 124: 931-8 (Pubitemid 40629093)
16. Fan E, Zhang L, Jiang S, et al. Beneficial effects of resveratrol on atherosclerosis. J Med Food 2008 Dec; 11 (4): 610-4
17. Dawber R. Skin surface biopsy and follicular cast. In: Serup J, Jemec GBE, editors. Handbook of non-invasive methods and the skin. Boca Raton (FL): Informa Healthcare, 1995: 121-3
18. Pagnoni A, Kligman AM, Stoudemayer T. Image analysis of cianoacrylate follicular biopsies. In: Wilhelm K-P, Elsner P, Berardesca E, et al., editors. Bioengineering of the skin: skin surface imaging and analysis. Boca Raton (FL): Informa Healthcare, 1997: 113-9
19. Witkowski J, Parish L. The assessment of acne: an evaluation of grading and lesion counting in the measurement of acne. Clin Dermatol 2004; 22: 394-7 (Pubitemid 39535281)
20. Chen X, He H, Wang G, et al. Stereospecific determination of cis- and transresveratrol in rat plasma by HPLC: application to pharmacokinetic studies. Biomed Chromatogr 2007 Mar; 21 (3): 257-65 (Pubitemid 46477466)
21. Wyckoff TJ, Raetz CR, Jackman JE. Antibacterial and anti-inflammatory agents that target endotoxin. Trends Microbiol 1998; 6: 154-9 (Pubitemid 28202433)
22. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273: 21875-82 (Pubitemid 28405365)
23. Donnelly LE, Newton R, Kennedy GE, et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physio Lung Cell Mol Physiol 2004; 287: L774-83
24. Lawrence M, Szewczuk, Luca Forti, et al. Stivala resveratrol is a peroxidasemediated inactivator of COX-1 but not COX-2 a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004; 279 (21): 22727-37
25. Holian O, Walter RJ. Resveratrol inhibits the proliferation of normal human keratinocytes in vitro. Cell Biochem 2001; Suppl. 36: 55-62
26. Fabbrocini G, Kisslinger A, Iannelli P, et al. Resveratrol regulates p66shc activation in HaCaT cells. Exp Dermatol 2010 Oct; 19 (10): 895-903
27. Kundu JK, Surh YJ. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat Res 2004; 555 (1-2): 65-80 (Pubitemid 39345398)
28. Gao X, Deeb D, Media J, et al. Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharmacol 2003; 66 (12): 2427-35 (Pubitemid 37456749)
29. Docherty JJ, Fu MM, Tsai M. Resveratrol selectively inhibits Neisseria gonorrhoeae andNeisseria meningitidis. JAntimicrob Chemother 2001; 47: 243-4 (Pubitemid 32149540)
30. Mahady GB, Pendland SL. Resveratrol inhibits growth of Helicobacter pylori in vitro [letter]. Am J Gastroenterol 2000; 95: 1849 (Pubitemid 30485041)
31. Chan MM. Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol 2002; 63: 99-104 (Pubitemid 34158808)
32. Wang WB, Lai HC, Hsueh PR, et al. Inhibition of swarming and virulence factor expression in Proteus mirabilis by resveratrol. J Med Microbiol 2006; 55: 1313-21
33. Docherty JJ, Heather A, McEwen Thomas J, et al. Resveratrol inhibition of Propionibacterium acnes. J Antimicrob Chem 2007; 59: 1182-4 (Pubitemid 47078720)